Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, and Johnson & Johnson. Learn more about health care stocks.

Eli Lilly and Company logo

#1 - Eli Lilly and Company

NYSE:LLY - See Stock Forecast
Stock Price:
$767.76 (+$10.22)
Market Cap:
$728.85 billion
P/E Ratio:
83.0
Dividend Yield:
0.67%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1,002.22 (30.5% Upside)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Eli Lilly and Company Stock

Pros

  • The stock has a "buy" rating from multiple analysts, including Bank of America, which suggests confidence in its future performance.
  • Recent earnings reports showed a year-over-year revenue increase of 20.4%, indicating strong growth potential.
  • The current stock price is approximately $799.58, which is below the average target price of around $1,002.22, suggesting potential for price appreciation.

Cons

  • The company reported earnings per share of $1.18, missing the consensus estimate of $1.52, which may raise concerns about its short-term performance.
  • Despite revenue growth, the company’s revenue of $11.44 billion for the quarter fell short of analyst expectations of $12.09 billion, indicating potential challenges in meeting market forecasts.
  • The stock has a relatively high P/E ratio of 86.44, which may suggest that it is overvalued compared to its earnings, posing a risk for investors.
UnitedHealth Group logo

#2 - UnitedHealth Group

NYSE:UNH - See Stock Forecast
Stock Price:
$500.13 (+$10.88)
Market Cap:
$460.26 billion
P/E Ratio:
32.6
Dividend Yield:
1.73%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 17 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$626.84 (25.3% Upside)
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of UnitedHealth Group Stock

Pros

  • Strong Earnings Performance: UnitedHealth Group recently reported earnings per share of $7.15, exceeding analysts' expectations of $7.00, indicating robust financial health and effective management.
  • Consistent Revenue Growth: The company achieved a revenue of $100.82 billion for the latest quarter, surpassing estimates and reflecting a year-over-year growth of 9.2%, showcasing its ability to expand in the competitive healthcare market.
  • Attractive Dividend Yield: UnitedHealth Group declared a quarterly dividend of $2.10, translating to an annualized yield of 1.60%. This consistent dividend payment can provide a steady income stream for investors.

Cons

  • Recent Stock Decline: The stock has experienced a decline of 3.3% recently, which may indicate market volatility or investor concerns about future performance.
  • High Debt-to-Equity Ratio: With a debt-to-equity ratio of 0.74, the company has a significant amount of debt compared to its equity, which could pose risks if interest rates rise or if the company faces financial challenges.
  • Market Competition: The healthcare sector is highly competitive, and UnitedHealth Group faces challenges from other major players, which could impact its market share and profitability.
Novo Nordisk A/S logo

#3 - Novo Nordisk A/S

NYSE:NVO - See Stock Forecast
Stock Price:
$85.00 (-$18.44)
Market Cap:
$381.44 billion
P/E Ratio:
27.5
Dividend Yield:
0.70%
Consensus Rating:
Buy (1 Strong Buy Ratings, 5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$150.40 (76.9% Upside)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novo Nordisk A/S Stock

Pros

  • Recent institutional interest has surged, with Wellington Management Group acquiring approximately $42 million in shares, indicating strong confidence in the company's future performance.
  • The stock is currently priced at $108.70, which is below its one-year high of $148.15, suggesting potential for price appreciation as the market recovers.
  • Analysts have recently upgraded their ratings, with Cantor Fitzgerald setting a price target of $160.00, reflecting optimism about the company's growth prospects.

Cons

  • The stock has recently experienced a decline of 2.7%, which may indicate short-term volatility and investor uncertainty.
  • Despite positive analyst ratings, one research analyst has issued a hold rating, suggesting that not all market participants are convinced of the stock's immediate upside.
  • With a price-to-earnings (P/E) ratio of 36.15, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
Johnson & Johnson logo

#4 - Johnson & Johnson

NYSE:JNJ - See Stock Forecast
Stock Price:
$144.47 (+$0.89)
Market Cap:
$347.83 billion
P/E Ratio:
20.9
Dividend Yield:
3.39%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 7 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$174.73 (20.9% Upside)
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Johnson & Johnson Stock

Pros

  • Johnson & Johnson has a strong market capitalization of $352.07 billion, indicating its stability and ability to weather market fluctuations.
  • The company recently reported earnings of $2.42 per share, exceeding analysts' expectations, which reflects its robust financial health and operational efficiency.
  • With a current stock price of $146.23, investors may find it an attractive entry point, especially considering the company's historical performance and growth potential.

Cons

  • The stock has experienced volatility, with a one-year low of $143.13, which may raise concerns about its short-term performance.
  • Johnson & Johnson's price-to-earnings (P/E) ratio of 21.28 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent insider trading activity, such as the purchase of 1,000 shares by a director, while positive, may also indicate that insiders are taking advantage of current prices, which could be a red flag for some investors.
AbbVie logo

#5 - AbbVie

NYSE:ABBV - See Stock Forecast
Stock Price:
$175.58 (+$4.06)
Market Cap:
$310.27 billion
P/E Ratio:
61.0
Dividend Yield:
3.54%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 17 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$205.70 (17.2% Upside)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AbbVie Stock

Pros

  • AbbVie has a strong market capitalization of approximately $308.14 billion, indicating a robust financial position and stability in the market.
  • The company reported earnings of $3.00 per share, exceeding analyst expectations, which reflects strong operational performance and profitability.
  • AbbVie has a diverse portfolio of products, including recent innovations that contribute to its revenue growth, with quarterly revenue reported at $14.46 billion.

Cons

  • AbbVie has a high price-to-earnings (P/E) ratio of 60.81, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • The company has a debt-to-equity ratio of 9.64, suggesting a high level of debt relative to equity, which could pose risks in times of economic downturns.
  • Recent price target reductions by analysts, with Citigroup lowering its target from $226.00 to $215.00, may indicate a bearish outlook on the stock's future performance.
Merck & Co., Inc. logo

#6 - Merck & Co., Inc.

NYSE:MRK - See Stock Forecast
Stock Price:
$98.05 (-$1.47)
Market Cap:
$248.03 billion
P/E Ratio:
20.6
Dividend Yield:
3.02%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 10 Buy Ratings, 7 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$127.13 (29.7% Upside)
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Merck & Co., Inc. Stock

Pros

  • Merck's stock price recently reached $102.00, indicating a stable market presence and potential for growth.
  • Institutional investors hold a significant 76.07% of Merck's stock, reflecting strong confidence in the company's future performance.
  • Merck has shown resilience with a market capitalization of approximately $258.02 billion, suggesting robust financial health and stability.

Cons

  • Merck's stock has experienced a 12-month high of $134.63, which may indicate that it is currently overvalued compared to its historical performance.
  • The company's 200-day moving average is $115.15, suggesting that the stock is trading below this average, which could be a sign of weakness.
  • Despite recent gains, the stock's price-to-earnings (P/E) ratio of 21.28 may be considered high, indicating that investors are paying a premium for earnings, which could limit future upside.
How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now
AstraZeneca logo

#7 - AstraZeneca

NASDAQ:AZN - See Stock Forecast
Stock Price:
$65.35 (+$0.91)
Market Cap:
$202.63 billion
P/E Ratio:
31.3
Dividend Yield:
1.52%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 6 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$89.75 (37.3% Upside)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of AstraZeneca Stock

Pros

  • AstraZeneca's stock recently traded at $68.20, showing a 1.0% increase, indicating positive market sentiment and potential for growth.
  • The company has received multiple upgrades from analysts, with a notable upgrade from UBS Group from a "sell" to a "neutral" rating, suggesting improved confidence in its performance.
  • TD Cowen raised the price target for AstraZeneca from $90.00 to $95.00, reflecting expectations of future growth and profitability.

Cons

  • The stock has a relatively high price-to-earnings (P/E) ratio of 32.62, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • AstraZeneca's 52-week trading range shows a low of $60.47, suggesting volatility and the potential for significant price fluctuations.
  • Despite recent upgrades, three analysts still rate the stock as a "hold," indicating uncertainty about its short-term performance.
Thermo Fisher Scientific logo

#8 - Thermo Fisher Scientific

NYSE:TMO - See Stock Forecast
Stock Price:
$524.05 (+$7.36)
Market Cap:
$200.45 billion
P/E Ratio:
32.9
Dividend Yield:
0.30%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 16 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$652.30 (24.5% Upside)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Thermo Fisher Scientific Stock

Pros

  • The stock has a consensus price target of $649.33, indicating potential for growth from its current trading levels.
  • Seventeen analysts have assigned a buy rating to the stock, reflecting strong market confidence in Thermo Fisher Scientific Inc.'s future performance.
  • The company has recently seen target price increases from several analysts, suggesting positive sentiment and expectations for its financial health.

Cons

  • Recent insider selling, with a total of 47,150 shares sold valued at approximately $25.95 million, may raise concerns about the executives' confidence in the company's short-term prospects.
  • Barclays and other analysts have recently lowered their price targets, which could indicate a shift in market sentiment or concerns about future performance.
  • The stock has experienced fluctuations, with recent sales occurring at an average price of $560.16, which may suggest volatility that could deter risk-averse investors.
Novartis logo

#9 - Novartis

NYSE:NVS - See Stock Forecast
Stock Price:
$97.11 (+$0.34)
Market Cap:
$198.49 billion
P/E Ratio:
11.3
Dividend Yield:
2.51%
Consensus Rating:
Reduce (0 Strong Buy Ratings, 0 Buy Ratings, 7 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$121.50 (25.1% Upside)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Novartis Stock

Pros

  • Novartis AG's stock is currently trading at $105.77, showing a recent increase of 0.9%. This positive price movement can indicate investor confidence and potential for further growth.
  • The company has a strong market capitalization of $216.19 billion, which reflects its stability and ability to withstand market fluctuations.
  • Recent analyst ratings show a consensus "Hold" rating with a price target averaging $121.50, suggesting that analysts believe the stock has room for growth without significant risk.

Cons

  • Several analysts have downgraded their ratings on Novartis AG, with Bank of America reducing its rating from "buy" to "neutral," which may indicate concerns about the company's future performance.
  • The stock has experienced fluctuations, with a 12-month low of $92.35, suggesting potential volatility that could deter risk-averse investors.
  • There is a notable presence of sell ratings among analysts, with two analysts rating the stock as a sell, which could reflect underlying issues that may affect the company's growth prospects.
Abbott Laboratories logo

#10 - Abbott Laboratories

NYSE:ABT - See Stock Forecast
Stock Price:
$114.23 (+$1.81)
Market Cap:
$198.13 billion
P/E Ratio:
34.7
Dividend Yield:
1.96%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 11 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$130.71 (14.4% Upside)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Abbott Laboratories Stock

Pros

  • Abbott Laboratories recently reported earnings of $1.21 per share, exceeding analysts' expectations, which indicates strong financial performance and effective management.
  • The company has a solid market capitalization of approximately $200 billion, reflecting its stability and growth potential in the healthcare sector.
  • Abbott Laboratories has a current stock price of $113.86, which is below the consensus price target of $130.07, suggesting potential for price appreciation.

Cons

  • The stock has a relatively high price-to-earnings (P/E) ratio of 34.51, which may suggest that it is overvalued compared to its earnings, potentially limiting future price growth.
  • Abbott Laboratories has a beta of 0.73, indicating lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Despite recent revenue growth of 4.9% year-over-year, the healthcare sector can be subject to regulatory changes and market fluctuations that may impact future earnings.
Intuitive Surgical logo

#11 - Intuitive Surgical

NASDAQ:ISRG - See Stock Forecast
Stock Price:
$524.43 (+$0.52)
Market Cap:
$186.79 billion
P/E Ratio:
84.3
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 15 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$554.17 (5.7% Upside)
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Intuitive Surgical Stock

Pros

  • Intuitive Surgical, Inc. reported a strong quarterly earnings per share (EPS) of $1.56, exceeding the consensus estimate of $1.24 by $0.32, indicating robust financial performance.
  • The company achieved revenue of $2.04 billion for the quarter, surpassing expectations and showcasing its ability to generate significant sales.
  • With a net margin of 28.51%, Intuitive Surgical, Inc. demonstrates effective cost management and profitability, which is attractive to investors looking for financially healthy companies.

Cons

  • The stock has a high price-to-earnings (P/E) ratio of 86.63, which may indicate that it is overvalued compared to its earnings, posing a risk for potential investors.
  • Insider selling has been notable, with over 50,000 shares sold in the last three months, which could signal a lack of confidence from those within the company.
  • Despite strong performance, the company has a relatively low return on equity of 13.41%, which may suggest less efficiency in generating profits from shareholders' equity.
Pfizer logo

#12 - Pfizer

NYSE:PFE - See Stock Forecast
Stock Price:
$26.36 (+$0.59)
Market Cap:
$149.38 billion
P/E Ratio:
35.6
Dividend Yield:
6.52%
Consensus Rating:
Hold (2 Strong Buy Ratings, 5 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$32.14 (21.9% Upside)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Pfizer Stock

Pros

  • Pfizer Inc. has a strong market capitalization of approximately $142.98 billion, indicating a robust financial position that can support growth and stability.
  • The stock is currently trading at $25.23, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Recent analyst ratings show a consensus average rating of "Moderate Buy," suggesting that many analysts believe the stock has potential for appreciation.

Cons

  • Wolfe Research has issued an "underperform" rating with a price target of $25.00, suggesting that the stock may not perform well in the near term.
  • Recent price targets from analysts vary significantly, with some as low as $25.00, indicating uncertainty about the stock's future performance.
  • The price-to-earnings (P/E) ratio of 34.31 is relatively high, which may suggest that the stock is overvalued compared to its earnings potential.
Amgen logo

#13 - Amgen

NASDAQ:AMGN - See Stock Forecast
Stock Price:
$263.38 (+$2.19)
Market Cap:
$141.58 billion
P/E Ratio:
33.7
Dividend Yield:
3.38%
Consensus Rating:
Hold (1 Strong Buy Ratings, 10 Buy Ratings, 12 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$319.67 (21.4% Upside)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Amgen Stock

Pros

  • Amgen Inc. has received multiple upgrades from analysts, with a recent upgrade from StockNews.com raising its rating from "buy" to "strong-buy," indicating strong confidence in the company's future performance.
  • The stock is currently trading at approximately $274.06, which is significantly lower than its one-year high of $346.85, suggesting potential for price appreciation as it approaches previous highs.
  • Institutional investors own 76.50% of Amgen Inc.'s stock, reflecting strong confidence from large financial entities in the company's stability and growth prospects.

Cons

  • Amgen Inc. has a high debt-to-equity ratio of 7.55, which indicates that the company relies heavily on debt financing. This could pose risks, especially in a rising interest rate environment.
  • Despite recent upgrades, two analysts have rated the stock with a "sell" rating, suggesting that there are concerns about its future performance that investors should consider.
  • The stock has experienced significant volatility, with a 50-day moving average of $303.87 compared to its current price, indicating that it may be overvalued at present levels.
Stryker logo

#14 - Stryker

NYSE:SYK - See Stock Forecast
Stock Price:
$364.60 (+$7.46)
Market Cap:
$138.99 billion
P/E Ratio:
39.1
Dividend Yield:
0.86%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 17 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$405.80 (11.3% Upside)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Stryker Stock

Pros

  • Stryker Co. recently reported earnings per share (EPS) of $2.87, exceeding analysts' expectations of $2.77, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 11.9%, reaching $5.49 billion, which reflects robust growth and demand for its medical technology products.
  • With a current stock price around $370.18, Stryker Co. is positioned well within its 52-week range, suggesting potential for appreciation as it approaches its 52-week high of $398.20.

Cons

  • The stock has a relatively high price-to-earnings (P/E) ratio of 41.77, which may suggest that the stock is overvalued compared to its earnings, potentially limiting future price appreciation.
  • Despite recent growth, the company's beta of 0.94 indicates that it is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • The dividend payout ratio (DPR) is at 34.30%, which, while sustainable, may limit the company's ability to reinvest profits into growth initiatives.
Boston Scientific logo

#15 - Boston Scientific

NYSE:BSX - See Stock Forecast
Stock Price:
$88.95 (+$0.29)
Market Cap:
$131.10 billion
P/E Ratio:
73.5
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 19 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$95.96 (7.9% Upside)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Boston Scientific Stock

Pros

  • Boston Scientific Co. has shown strong financial performance, with a revenue increase of 19.3% compared to the same quarter last year, indicating robust growth in its medical device market.
  • The company has a solid return on equity of 17.23%, which suggests effective management and profitability relative to shareholder equity, making it an attractive option for investors seeking returns.
  • Recent analyst upgrades have boosted the target price for Boston Scientific Co. to as high as $110.00, reflecting positive market sentiment and potential for stock appreciation.

Cons

  • Despite positive growth, the stock has experienced insider selling, with executives selling over 328,157 shares worth nearly $28 million in the last ninety days, which could signal a lack of confidence in the company's short-term prospects.
  • Recent downgrades from analysts, including a shift from a "buy" to a "hold" rating, may indicate potential challenges ahead for the company's stock performance.
  • The company's debt-to-equity ratio stands at 0.44, which, while manageable, suggests that Boston Scientific Co. is somewhat reliant on debt financing, potentially increasing financial risk.
Sanofi logo

#16 - Sanofi

NASDAQ:SNY - See Stock Forecast
Stock Price:
$47.71 (+$0.21)
Market Cap:
$121.08 billion
P/E Ratio:
24.3
Dividend Yield:
3.11%
Consensus Rating:
Buy (1 Strong Buy Ratings, 1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$57.50 (20.5% Upside)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Sanofi Stock

Pros

  • Sanofi recently reported earnings per share (EPS) of $1.57, significantly exceeding analysts' expectations of $0.22, indicating strong financial performance and effective management.
  • The company has shown a year-over-year revenue increase of 12.3%, demonstrating growth potential and resilience in its business operations.
  • With a current stock price of $48.51, Sanofi is trading within a reasonable range compared to its 12-month high of $58.97, suggesting potential for price appreciation.

Cons

  • Despite the positive EPS report, Sanofi's revenue of $13.44 billion fell short of analysts' expectations of $16.59 billion, raising concerns about future sales growth.
  • The stock has a relatively high price-to-earnings (P/E) ratio of 24.72, which may suggest that the stock is overvalued compared to its earnings, potentially limiting upside for new investors.
  • Sanofi's beta of 0.58 indicates lower volatility compared to the market, which may not appeal to investors seeking high-growth opportunities in more dynamic sectors.
Bristol-Myers Squibb logo

#17 - Bristol-Myers Squibb

NYSE:BMY - See Stock Forecast
Stock Price:
$57.33 (+$1.03)
Market Cap:
$116.28 billion
Dividend Yield:
4.26%
Consensus Rating:
Hold (2 Strong Buy Ratings, 3 Buy Ratings, 13 Hold Ratings, 2 Sell Ratings)
Consensus Price Target:
$55.64 (-2.9% Downside)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Bristol-Myers Squibb Stock

Pros

  • Bristol-Myers Squibb has a strong portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which positions the company well in the growing pharmaceutical market.
  • The company has received upgrades from multiple equities research analysts, indicating positive sentiment and potential for stock price appreciation. For instance, Leerink Partners upgraded the stock to a "strong-buy" rating recently.
  • Current stock price is around $54.29, which is considered attractive given the company's robust product pipeline and market position, suggesting potential for growth.

Cons

  • Despite recent upgrades, the stock has received a consensus rating of "Hold," indicating that many analysts are cautious about its short-term performance.
  • There are concerns regarding the competitive landscape in the biopharmaceutical industry, which could impact Bristol-Myers Squibb's market share and pricing power.
  • Some analysts have issued sell ratings, reflecting skepticism about the company's ability to maintain growth in the face of patent expirations and generic competition.
Gilead Sciences logo

#18 - Gilead Sciences

NASDAQ:GILD - See Stock Forecast
Stock Price:
$92.57 (+$1.48)
Market Cap:
$115.37 billion
P/E Ratio:
1,028.6
Dividend Yield:
3.40%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 12 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$96.43 (4.2% Upside)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Gilead Sciences Stock

Pros

  • The current stock price is approximately $92.76, which may present a buying opportunity for investors looking for growth in the biopharmaceutical sector.
  • Gilead Sciences, Inc. has a strong pipeline of innovative medicines targeting unmet medical needs, which can lead to significant revenue growth as these products gain market approval.
  • Recent insider trading activity indicates confidence in the company's future, as executives have been actively managing their stock holdings, suggesting they believe in the company's long-term value.

Cons

  • Insider sales have been significant, with over 447,234 shares sold recently, which may raise concerns about the executives' confidence in the company's short-term performance.
  • The company has experienced a notable decrease in insider ownership, with some executives reducing their stakes by over 64%, which could signal potential issues or lack of confidence in future growth.
  • Market competition in the biopharmaceutical industry is intense, and Gilead Sciences, Inc. faces challenges from other companies developing similar therapies, which could impact market share and profitability.
Medtronic logo

#19 - Medtronic

NYSE:MDT - See Stock Forecast
Stock Price:
$81.03 (+$1.04)
Market Cap:
$103.90 billion
P/E Ratio:
24.8
Dividend Yield:
3.50%
Consensus Rating:
Hold (1 Strong Buy Ratings, 6 Buy Ratings, 9 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$95.00 (17.2% Upside)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Medtronic Stock

Pros

  • Medtronic plc recently reported a quarterly earnings per share (EPS) of $1.26, exceeding analysts' expectations of $1.25, indicating strong financial performance and effective management.
  • The company has a solid revenue stream, with reported revenue of $8.40 billion for the latest quarter, surpassing estimates and reflecting a year-over-year growth of 5.2%.
  • Medtronic plc has a current stock price of $84.01, which is below the consensus target price of $95.27, suggesting potential for price appreciation.

Cons

  • Despite recent positive earnings, the stock has experienced volatility, with a 52-week low of $75.96, which may raise concerns about its stability.
  • The company's debt-to-equity ratio stands at 0.51, which, while manageable, indicates that Medtronic plc is utilizing debt to finance its operations, potentially increasing financial risk.
  • Analysts have issued a sell rating from one analyst, suggesting that there are concerns about the stock's future performance.
Vertex Pharmaceuticals logo

#20 - Vertex Pharmaceuticals

NASDAQ:VRTX - See Stock Forecast
Stock Price:
$397.27 (+$0.63)
Market Cap:
$102.31 billion
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 10 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$499.77 (25.8% Upside)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Vertex Pharmaceuticals Stock

Pros

  • Vertex Pharmaceuticals Incorporated reported a strong quarterly earnings performance, with earnings per share of $4.38, surpassing the consensus estimate by $0.77. This indicates robust financial health and effective management.
  • The company has shown a year-over-year revenue increase of 11.6%, reaching $2.77 billion, which reflects its growing market presence and successful product offerings.
  • With a current stock price of $469.22, the stock is trading near its 52-week high of $519.88, suggesting potential for further appreciation as market conditions evolve.

Cons

  • The company has a negative return on equity of 1.91% and a negative net margin of 4.52%, indicating challenges in profitability that could concern potential investors.
  • Vertex Pharmaceuticals Incorporated has a PE ratio of -233.23, which suggests that the company is currently not generating profits relative to its stock price, making it a riskier investment.
  • Despite recent revenue growth, the company is projected to post an EPS of -1.83 for the current fiscal year, which may signal ongoing financial difficulties.
Elevance Health logo

#21 - Elevance Health

NYSE:ELV - See Stock Forecast
Stock Price:
$365.96 (-$0.52)
Market Cap:
$84.87 billion
P/E Ratio:
13.3
Dividend Yield:
1.78%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 12 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$539.20 (47.3% Upside)
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.
Regeneron Pharmaceuticals logo

#22 - Regeneron Pharmaceuticals

NASDAQ:REGN - See Stock Forecast
Stock Price:
$701.85 (-$6.40)
Market Cap:
$77.13 billion
P/E Ratio:
17.4
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 15 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$1,052.90 (50.0% Upside)
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Regeneron Pharmaceuticals Stock

Pros

  • Regeneron Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock's future performance.
  • The current stock price is $778.50, which is significantly lower than its 52-week high of $1,211.20, suggesting potential for price appreciation as the market recovers.
  • Seventeen analysts have assigned a buy rating to the stock, reflecting confidence in the company's growth prospects and product pipeline.

Cons

  • Recent price target reductions by multiple analysts, including Oppenheimer lowering it from $1,150.00 to $1,000.00, may signal concerns about the company's near-term performance.
  • One analyst has rated the stock with a sell rating, which could indicate potential risks or challenges that investors should consider.
  • The stock has experienced significant volatility, with a 52-week low of $735.95, suggesting uncertainty in its price movements.
The Cigna Group logo

#23 - The Cigna Group

NYSE:CI - See Stock Forecast
Stock Price:
$276.92 (+$2.12)
Market Cap:
$77.03 billion
P/E Ratio:
26.1
Dividend Yield:
2.11%
Consensus Rating:
Buy (1 Strong Buy Ratings, 13 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$394.64 (42.5% Upside)
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of The Cigna Group Stock

Pros

  • The Cigna Group recently reported earnings per share of $7.51, exceeding analysts' expectations of $7.22, indicating strong financial performance and effective management.
  • The company achieved a revenue of $63.70 billion for the latest quarter, significantly higher than the anticipated $59.58 billion, showcasing robust growth and demand for its services.
  • With a current stock price of $293.94, The Cigna Group is trading below several analysts' target prices, suggesting potential for price appreciation as the market corrects.

Cons

  • The stock has recently experienced a decline of 5.6%, which may indicate underlying issues or market volatility that could affect future performance.
  • The company's net margin is relatively low at 1.31%, suggesting that while revenues are high, profitability may be constrained, which could impact long-term growth.
  • Despite a strong performance, one analyst has rated the stock as a hold, indicating some caution among market experts regarding its future potential.
HCA Healthcare logo

#24 - HCA Healthcare

NYSE:HCA - See Stock Forecast
Stock Price:
$303.62 (+$6.10)
Market Cap:
$76.91 billion
P/E Ratio:
13.6
Dividend Yield:
0.86%
Consensus Rating:
Moderate Buy (2 Strong Buy Ratings, 11 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$385.63 (27.0% Upside)
HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of HCA Healthcare Stock

Pros

  • HCA Healthcare, Inc. has a strong dividend yield of 0.83%, providing a steady income stream for investors.
  • The company has a low payout ratio of 11.85%, indicating that it retains a significant portion of its earnings for growth and reinvestment.
  • Recent analyst upgrades have boosted price targets, with firms like Truist Financial setting a target of $430.00, suggesting potential for price appreciation.

Cons

  • Some analysts have downgraded their ratings, with Wells Fargo reducing their target price to $320.00, indicating potential concerns about future performance.
  • Insider sales have totaled 15,155 shares worth over $5.6 million in the last quarter, which could signal a lack of confidence among some executives.
  • The company has a high debt-to-equity ratio of 48.71, suggesting that it relies heavily on debt financing, which can be risky in volatile markets.
Zoetis logo

#25 - Zoetis

NYSE:ZTS - See Stock Forecast
Stock Price:
$164.84 (+$1.32)
Market Cap:
$73.77 billion
P/E Ratio:
31.0
Dividend Yield:
1.03%
Consensus Rating:
Buy (2 Strong Buy Ratings, 8 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$215.22 (30.6% Upside)
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Zoetis Stock

Pros

  • Zoetis Inc. has shown strong financial performance, reporting a quarterly revenue of $2.40 billion, which exceeded analysts' expectations of $2.29 billion. This indicates robust demand for its products and effective management.
  • The company recently achieved earnings per share of $1.58, surpassing the consensus estimate of $1.46 by $0.12. This positive earnings surprise can enhance investor confidence and potentially lead to stock price appreciation.
  • As of the latest trading session, Zoetis Inc. shares are priced at $176.46, reflecting a solid market position and investor interest, which could be attractive for potential buyers looking for growth opportunities.

Cons

  • The stock has a relatively high price-to-earnings (P/E) ratio of 33.17, which may suggest that it is overvalued compared to its earnings. This could deter value-focused investors.
  • Despite recent growth, the company has a debt-to-equity ratio of 1.26, indicating that it has taken on a significant amount of debt relative to its equity. This could pose risks if the company faces financial challenges.
  • Zoetis Inc. has experienced fluctuations in its stock price, with a 12-month high of $201.92 and a low of $144.80, which may indicate volatility that could concern risk-averse investors.
McKesson logo

#26 - McKesson

NYSE:MCK - See Stock Forecast
Stock Price:
$579.74 (+$0.52)
Market Cap:
$73.53 billion
P/E Ratio:
30.0
Dividend Yield:
0.50%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 13 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$650.14 (12.1% Upside)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of McKesson Stock

Pros

  • McKesson Co. has shown strong institutional support, with 85.07% of its stock owned by institutional investors, indicating confidence in the company's future performance.
  • The stock is currently trading at $576.40, which is near its 12-month high of $637.51, suggesting a robust market position and potential for further growth.
  • Recent insider trading activity shows that executives are actively managing their positions, with a notable sale by EVP Leann B. Smith, which can indicate a strategic approach to stock management.

Cons

  • Despite the strong institutional ownership, the recent sale of shares by Barclays PLC, which reduced its stake by 18.5%, may raise concerns about the stock's short-term outlook.
  • The stock has experienced fluctuations, with a 12-month low of $431.35, indicating potential volatility that could deter some investors.
  • Insider ownership is relatively low at 0.11%, which may suggest a lack of alignment between management and shareholder interests.
Aetna logo

#27 - Aetna

NYSE:AET - See Stock Forecast
Stock Price:
$212.70
Market Cap:
$69.64 billion
P/E Ratio:
21.6
Dividend Yield:
0.94%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis. It also provides point-of-service, preferred provider organization, health maintenance organization, and indemnity benefit plans, as well as health savings accounts and consumer-directed health plans. In addition, this segment offers Medicare and Medicaid products and services, as well as other medical products, such as medical management and data analytics services, medical stop loss insurance, workers' compensation administrative services, and products that provide access to its provider networks in select geographies. The Group Insurance segment offers life insurance products, including group term life insurance, voluntary spouse and dependent term life insurance, group universal life insurance, and accidental death and dismemberment insurance; disability insurance products; and long-term care insurance products, which provide the benefits to cover the cost of care in private home settings, adult day care, assisted living, or nursing facilities. The Large Case Pensions segment manages various retirement products comprising pension and annuity products primarily for tax-qualified pension plans. The company provides its products and services to employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Aetna Inc. was founded in 1853 and is based in Hartford, Connecticut.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Aetna Stock

Pros

  • Aetna Inc. has a diverse range of health care products, including medical, pharmacy benefit management, and dental plans, which positions it well in the growing health care market.
  • The company has been expanding its Medicare and Medicaid offerings, tapping into the increasing demand for government-sponsored health care services.
  • As of December 2024, Aetna Inc.'s stock price is $XX. This reflects a strong performance in the market, indicating investor confidence and potential for growth.

Cons

  • The health care industry is highly regulated, and changes in government policies can impact Aetna Inc.'s operations and profitability.
  • Increased competition from other health care providers and insurance companies may pressure Aetna Inc.'s market share and pricing strategies.
  • Recent economic uncertainties could lead to reduced consumer spending on health care services, potentially affecting Aetna Inc.'s revenue streams.
GSK logo

#28 - GSK

NYSE:GSK - See Stock Forecast
Stock Price:
$33.60 (+$0.17)
Market Cap:
$69.64 billion
P/E Ratio:
21.8
Dividend Yield:
4.53%
Consensus Rating:
Moderate Buy (3 Strong Buy Ratings, 0 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$43.25 (28.7% Upside)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of GSK Stock

Pros

  • GSK plc recently announced an increase in its quarterly dividend to $0.3928, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend yield of 4.63%, which is attractive for income-focused investors.
  • The stock is currently trading at $34.44, which is significantly below its 52-week high of $45.92. This may present a buying opportunity for investors looking for potential upside as the stock could rebound towards its previous highs.
  • Institutional interest in GSK plc remains strong, with several hedge funds increasing their stakes recently. For instance, FMR LLC boosted its holdings by 8.3%, indicating confidence in the company's future performance.

Cons

  • GSK plc's stock has recently experienced a decline of 2.2%, indicating potential volatility and uncertainty in the market, which could deter risk-averse investors.
  • The company's debt-to-equity ratio stands at 0.98, which is relatively high and may raise concerns about financial leverage and the ability to manage debt effectively.
  • Despite the increase in dividends, GSK plc's payout ratio is 99.35%, suggesting that the company is distributing nearly all of its earnings to shareholders, which could limit reinvestment in growth opportunities.
Becton, Dickinson and Company logo

#29 - Becton, Dickinson and Company

NYSE:BDX - See Stock Forecast
Stock Price:
$227.68 (+$3.85)
Market Cap:
$65.83 billion
P/E Ratio:
38.3
Dividend Yield:
1.83%
Consensus Rating:
Buy (0 Strong Buy Ratings, 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$283.50 (24.5% Upside)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Becton, Dickinson and Company Stock

Pros

  • Recent institutional interest has surged, with Neo Ivy Capital Management acquiring 7,010 shares valued at approximately $1,690,000, indicating strong confidence in the company's future performance.
  • The stock has received positive ratings from multiple analysts, with an average rating of "Buy" and a price target of $283.50, suggesting potential for price appreciation.
  • Becton, Dickinson and Company reported a strong quarterly earnings performance, with an EPS of $3.81, exceeding analyst expectations, which reflects robust operational efficiency and profitability.

Cons

  • The stock has recently experienced a decline, trading down 1.0% to $219.16, which may signal weakness in market sentiment.
  • Despite strong earnings, the company has a relatively high P/E ratio of 37.28, which could indicate that the stock is overvalued compared to its earnings.
  • There has been a reduction in holdings by some institutional investors, such as Orion Portfolio Solutions LLC, which decreased its position by 17.9%, potentially reflecting concerns about future performance.
Allergan logo

#30 - Allergan

NYSE:AGN - See Stock Forecast
Stock Price:
$193.02
Market Cap:
$63.50 billion
Dividend Yield:
1.53%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Allergan Stock

Pros

  • Allergan plc has a diverse portfolio of products across various therapeutic areas, including medical aesthetics, eye care, and neuroscience, which can provide stability and growth potential in different market conditions.
  • The company is actively developing innovative treatments, such as RST-001, a novel gene therapy for retinitis pigmentosa, which could position it as a leader in emerging therapeutic areas.
  • Allergan plc's collaboration with Editas Medicine, Inc. for gene editing technologies may enhance its research capabilities and lead to breakthrough therapies, potentially increasing its market value.

Cons

  • Allergan plc faces significant competition in the pharmaceutical industry, which could impact its market share and pricing power for its products.
  • The company is subject to regulatory scrutiny, and any delays or rejections in product approvals could adversely affect its financial performance.
  • Recent developments in the pharmaceutical sector indicate a trend towards consolidation, which may pose risks for Allergan plc in maintaining its independence and strategic direction.
Shire logo

#31 - Shire

NASDAQ:SHPG - See Stock Forecast
Stock Price:
$179.20
Market Cap:
$54.71 billion
P/E Ratio:
11.8
Dividend Yield:
0.19%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc., as well as a preclinical research collaboration agreement with NanoMedSyn. The company was founded in 1986 and is headquartered in Dublin, Ireland.
Express Scripts logo

#32 - Express Scripts

NASDAQ:ESRX - See Stock Forecast
Stock Price:
$92.33
Market Cap:
$52.06 billion
P/E Ratio:
13.0
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Express Scripts Stock

Pros

  • Express Scripts Holding operates a comprehensive pharmacy benefit management (PBM) system, which is essential for managing prescription drug benefits for various health plans, potentially leading to stable revenue streams.
  • The company has a strong focus on clinical solutions and specialized pharmacy care, which can enhance patient outcomes and reduce overall healthcare costs, making it an attractive partner for health insurers and employers.
  • Recent developments indicate that Express Scripts Holding is actively involved in legal proceedings against the FTC, which could impact its market position and operational strategies, presenting an opportunity for investors to capitalize on potential outcomes.

Cons

  • The ongoing lawsuit against the FTC could lead to regulatory challenges and uncertainties that may negatively impact the company's operations and stock performance.
  • As a PBM, Express Scripts Holding faces intense competition from other healthcare service providers, which could pressure profit margins and market share.
  • Changes in healthcare regulations and policies, particularly those affecting drug pricing and reimbursement, could pose risks to the company's business model and profitability.
Edwards Lifesciences logo

#33 - Edwards Lifesciences

NYSE:EW - See Stock Forecast
Stock Price:
$74.81 (+$0.88)
Market Cap:
$44.12 billion
P/E Ratio:
10.8
Consensus Rating:
Hold (0 Strong Buy Ratings, 11 Buy Ratings, 15 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$79.40 (6.1% Upside)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Edwards Lifesciences Stock

Pros

  • Wellington Management Group LLP recently increased its holdings in Edwards Lifesciences Co. by 86.3%, indicating strong institutional confidence in the company's future performance.
  • The stock has a current price of $71.53, which may present a buying opportunity for investors looking for potential growth as analysts have set an average target price of $78.65.
  • Edwards Lifesciences Co. reported a year-over-year revenue increase of 8.9%, showcasing its ability to grow despite market challenges, which is a positive sign for long-term investors.

Cons

  • Despite the revenue growth, the company reported earnings that met consensus estimates but fell short of revenue expectations, which may raise concerns about its ability to meet future growth targets.
  • Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the stock's short-term performance.
  • The stock has experienced a decline of 1.2% recently, which may indicate volatility and potential challenges in maintaining investor confidence.
Cencora logo

#34 - Cencora

NYSE:COR - See Stock Forecast
Stock Price:
$227.69 (+$1.42)
Market Cap:
$44.01 billion
P/E Ratio:
30.3
Dividend Yield:
0.97%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$275.60 (21.0% Upside)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Cencora Stock

Pros

  • The stock has a current price of $248.47, which reflects a strong market position and investor interest.
  • Cencora, Inc. has recently increased its quarterly dividend to $0.55, up from $0.51, indicating a commitment to returning value to shareholders.
  • Analysts have a consensus rating of "Moderate Buy" for the stock, with a target price of $276.80, suggesting potential for price appreciation.

Cons

  • The stock has a relatively high price-to-earnings (P/E) ratio of 33.09, which may indicate that it is overvalued compared to its earnings.
  • Cencora, Inc. has a high debt-to-equity ratio of 4.84, suggesting that the company relies heavily on debt financing, which can be risky in volatile markets.
  • Insider selling has been significant, with 93,018 shares sold recently, which may raise concerns about the confidence of insiders in the company's future performance.
Haleon logo

#35 - Haleon

NYSE:HLN - See Stock Forecast
Stock Price:
$9.69 (-$0.01)
Market Cap:
$43.86 billion
P/E Ratio:
28.5
Dividend Yield:
1.09%
Consensus Rating:
Buy (1 Strong Buy Ratings, 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$10.95 (13.0% Upside)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Haleon Stock

Pros

  • Haleon plc has received multiple upgrades from investment analysts, including a "strong-buy" rating from UBS Group, indicating strong confidence in the company's future performance.
  • The stock currently trades at $9.39, which is above its 12-month low of $7.89, suggesting a potential for growth as it approaches its 12-month high of $10.80.
  • With a market capitalization of $42.51 billion, Haleon plc is positioned as a significant player in the consumer healthcare market, which can provide stability and growth opportunities.

Cons

  • The downgrade from Goldman Sachs from a "buy" to a "neutral" rating may signal potential concerns about the company's short-term performance.
  • Haleon plc has a relatively high price-to-earnings (P/E) ratio of 27.34, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
  • The company's quick ratio of 0.58 suggests that it may struggle to meet short-term liabilities, which could be a red flag for investors concerned about liquidity.
Seagen logo

#36 - Seagen

NASDAQ:SGEN - See Stock Forecast
Stock Price:
$228.74
Market Cap:
$42.93 billion
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Seagen Stock

Pros

  • Seagen Inc. has a strong portfolio of innovative cancer therapies, including ADCETRIS and PADCEV, which are well-established in the market and have shown significant efficacy in treating various cancers.
  • The company is actively developing new treatments, such as TIVDAK for metastatic cervical cancer, which could expand its market reach and revenue potential.
  • As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc., providing it with additional resources and support for research and development, which could enhance its growth prospects.

Cons

  • The biotechnology sector is highly competitive, and Seagen Inc. faces challenges from other companies developing similar cancer therapies, which could impact its market share.
  • Regulatory hurdles can delay the approval of new drugs, and any setbacks in the approval process for Seagen Inc.'s pipeline products could negatively affect its stock performance.
  • As a subsidiary of Pfizer Inc., Seagen Inc. may have less autonomy in decision-making, which could limit its ability to pursue independent strategic initiatives.
Alcon logo

#37 - Alcon

NYSE:ALC - See Stock Forecast
Stock Price:
$84.76 (+$0.58)
Market Cap:
$41.81 billion
P/E Ratio:
36.2
Dividend Yield:
0.31%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 11 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$102.72 (21.2% Upside)
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alcon Stock

Pros

  • Alcon Inc. has shown a strong fifty-two week performance of 26.72%, indicating a positive trend in its stock price over the past year, which can attract investors looking for growth.
  • The current stock price is $91.98, which reflects the company's market valuation and can be seen as a point of entry for potential investors.
  • With an average daily volume of 695,900 shares, there is significant trading activity, suggesting liquidity and ease of buying or selling shares.

Cons

  • There has been a month-to-month decrease in shares shorted, from 3,430,000 to 3,160,000, which may indicate a lack of confidence in the stock's upward movement.
  • The institutional ownership percentage dropped to 0%, which could suggest a lack of confidence from institutional investors, potentially leading to volatility.
  • Despite a positive performance, the average daily volume has decreased from 810,500 to 695,900, indicating reduced trading interest, which could affect liquidity.
Takeda Pharmaceutical logo

#38 - Takeda Pharmaceutical

NYSE:TAK - See Stock Forecast
Stock Price:
$13.10 (+$0.09)
Market Cap:
$41.40 billion
P/E Ratio:
22.6
Dividend Yield:
4.08%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Takeda Pharmaceutical Stock

Pros

  • Recent investment activity indicates strong institutional interest, with XTX Topco Ltd acquiring a stake valued at approximately $957,000, suggesting confidence in the company's future performance.
  • Takeda Pharmaceutical Company Limited's stock price recently reached $13.57, reflecting a 0.8% increase, which may indicate positive market sentiment and potential for further growth.
  • The company has a solid market capitalization of approximately $43.16 billion, which can provide stability and resources for ongoing research and development initiatives.

Cons

  • The company's current debt-to-equity ratio stands at 0.64, which, while manageable, indicates that a significant portion of its financing comes from debt, potentially increasing financial risk.
  • Despite recent stock price increases, Takeda Pharmaceutical Company Limited has a P/E ratio of 23.45, which may suggest that the stock is overvalued compared to its earnings, raising concerns for value investors.
  • With a current ratio of 1.28 and a quick ratio of 0.77, there may be concerns about the company's short-term liquidity and ability to meet its immediate financial obligations.
Alexion Pharmaceuticals logo

#39 - Alexion Pharmaceuticals

NASDAQ:ALXN - See Stock Forecast
Stock Price:
$182.50
Market Cap:
$40.34 billion
P/E Ratio:
59.6
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alexion Pharmaceuticals Stock

Pros

  • Recent acquisition by AstraZeneca for $39 billion indicates strong market confidence in Alexion Pharmaceuticals, Inc.'s value and potential for growth.
  • Current stock price reflects a significant investment opportunity, as the acquisition suggests a premium valuation that could lead to increased investor interest.
  • Alexion Pharmaceuticals, Inc. has a robust pipeline of innovative therapies, which positions the company well for future revenue growth and market expansion.

Cons

  • The recent data breach involving patient information raises concerns about the company's data security measures and could impact its reputation and trust with stakeholders.
  • Integration challenges following the acquisition by AstraZeneca may create operational uncertainties that could affect performance in the short term.
  • Market volatility and regulatory scrutiny in the pharmaceutical industry could pose risks to Alexion Pharmaceuticals, Inc.'s stock performance and growth prospects.
argenx logo

#40 - argenx

NASDAQ:ARGX - See Stock Forecast
Stock Price:
$623.82 (-$2.21)
Market Cap:
$37.66 billion
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 18 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$639.78 (2.6% Upside)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of argenx Stock

Pros

  • argenx SE reported earnings per share of $1.39 for the latest quarter, significantly exceeding analysts' expectations of $0.10, indicating strong financial performance and potential for growth.
  • The company achieved revenue of $588.88 million, surpassing analyst estimates of $543.29 million, showcasing its ability to generate higher-than-expected sales.
  • Analysts have a consensus rating of "Moderate Buy" for argenx SE, with a consensus price target of approximately $635.42, suggesting that the stock is expected to appreciate in value.

Cons

  • Despite the positive earnings report, argenx SE has a negative net margin of 2.11%, indicating that the company is currently spending more than it earns, which could be a concern for profitability.
  • The company has a negative return on equity of 1.45%, suggesting that it is not effectively generating profits from its equity investments, which may deter some investors.
  • There has been a downgrade from a "strong-buy" to a "hold" rating by Baird R W, indicating that some analysts may have concerns about the stock's short-term performance.
How to piss off your liberal friends… and profit from it (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now
GE HealthCare Technologies logo

#41 - GE HealthCare Technologies

NASDAQ:GEHC - See Stock Forecast
Stock Price:
$78.91 (+$1.48)
Market Cap:
$36.05 billion
P/E Ratio:
21.7
Dividend Yield:
0.15%
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 8 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$95.46 (21.0% Upside)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of GE HealthCare Technologies Stock

Pros

  • Recent strong earnings performance, with the company reporting $1.14 earnings per share (EPS) for the latest quarter, exceeding the consensus estimate of $1.06 by $0.08, indicating robust profitability.
  • Current stock price is $83.01, which may present a buying opportunity for investors looking for growth in the healthcare technology sector.
  • Institutional ownership is high at 82.06%, suggesting confidence from large investors in the company's future performance.

Cons

  • Despite recent earnings growth, the company has a price-to-earnings (P/E) ratio of 22.80, which may be considered high compared to industry averages, potentially indicating overvaluation.
  • UBS Group recently downgraded the stock from "neutral" to "sell," lowering their price target from $84.00 to $74.00, which could signal a bearish outlook from some analysts.
  • The stock has experienced volatility, with a twelve-month low of $67.00, suggesting potential risks for investors regarding price stability.
IQVIA logo

#42 - IQVIA

NYSE:IQV - See Stock Forecast
Stock Price:
$197.27 (+$5.75)
Market Cap:
$35.80 billion
P/E Ratio:
25.9
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 17 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$255.82 (29.7% Upside)
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of IQVIA Stock

Pros

  • Recent institutional investment activity indicates strong confidence in IQVIA Holdings Inc., with MML Investors Services LLC increasing its stake by 6.3%, reflecting a positive outlook on the company's future performance.
  • The stock is currently trading at $206.57, which is significantly below its 12-month high of $261.73, suggesting potential for price appreciation as the market recognizes the company's value.
  • IQVIA Holdings Inc. has a high percentage of institutional ownership at 89.62%, which often indicates stability and confidence from large investors, potentially leading to less volatility in the stock price.

Cons

  • The company has a debt-to-equity ratio of 1.76, indicating a higher level of debt compared to equity, which could pose risks if the company faces financial challenges or if interest rates rise.
  • Recent price target reductions by analysts, such as JPMorgan Chase lowering its target from $279.00 to $240.00, may signal concerns about the company's near-term performance and market conditions.
  • IQVIA Holdings Inc. has a quick ratio of 0.81, which is below 1, suggesting that the company may not have enough liquid assets to cover its short-term liabilities, raising concerns about its liquidity position.
ResMed logo

#43 - ResMed

NYSE:RMD - See Stock Forecast
Stock Price:
$237.27 (+$5.69)
Market Cap:
$34.83 billion
P/E Ratio:
31.4
Dividend Yield:
0.87%
Consensus Rating:
Hold (1 Strong Buy Ratings, 5 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$227.91 (-3.9% Downside)
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of ResMed Stock

Pros

  • Strong Earnings Performance: ResMed Inc. reported earnings per share (EPS) of $2.20, exceeding the consensus estimate of $2.03 by $0.17, indicating robust financial health and effective management.
  • Revenue Growth: The company achieved quarterly revenue of $1.22 billion, surpassing analyst expectations of $1.19 billion, reflecting a year-over-year revenue increase of 11.1%.
  • Attractive Dividend: ResMed Inc. announced a quarterly dividend of $0.53 per share, translating to an annualized dividend of $2.12 and a yield of 0.87%, providing a steady income stream for investors.

Cons

  • Insider Selling: Recent insider sales of 68,334 shares worth over $16 million may raise concerns about the company's future prospects and insider confidence.
  • Moderate Buy Rating: While the stock has received upgrades, the average rating remains a "Moderate Buy," which may indicate a lack of overwhelming confidence among analysts.
  • Dividend Payout Ratio: The company's payout ratio stands at 28.08%, which, while sustainable, may limit the potential for future dividend increases if earnings do not grow significantly.
IDEXX Laboratories logo

#44 - IDEXX Laboratories

NASDAQ:IDXX - See Stock Forecast
Stock Price:
$412.26 (+$3.23)
Market Cap:
$33.76 billion
P/E Ratio:
39.8
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 7 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$539.63 (30.9% Upside)
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of IDEXX Laboratories Stock

Pros

  • IDEXX Laboratories, Inc. reported earnings per share of $2.80, exceeding the consensus estimate of $2.69, indicating strong financial performance and effective management.
  • The company achieved a net margin of 22.53%, showcasing its ability to convert revenue into profit efficiently, which is attractive for investors looking for profitability.
  • With a current stock price of $434.43, IDEXX Laboratories, Inc. has shown resilience in the market, reflecting investor confidence and potential for future growth.

Cons

  • The company's revenue of $975.50 million fell short of the consensus estimate of $980.32 million, indicating potential challenges in meeting market expectations.
  • Analysts have recently adjusted their price targets downward, with JPMorgan reducing its target from $630.00 to $575.00, which may signal concerns about future growth prospects.
  • Despite a strong earnings report, the stock has a high price-to-earnings ratio of 41.89, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
Alnylam Pharmaceuticals logo

#45 - Alnylam Pharmaceuticals

NASDAQ:ALNY - See Stock Forecast
Stock Price:
$245.44 (+$6.57)
Market Cap:
$31.66 billion
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 18 Buy Ratings, 5 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$298.09 (21.5% Upside)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Alnylam Pharmaceuticals Stock

Pros

  • Alnylam Pharmaceuticals, Inc. has a strong market capitalization of $33.05 billion, indicating a robust position in the biopharmaceutical sector, which can provide stability and growth potential for investors.
  • The company focuses on innovative therapeutics based on ribonucleic acid interference, a cutting-edge area in medicine that could lead to significant advancements in treatment options and market opportunities.
  • Despite recent earnings challenges, the stock price has shown resilience, currently trading around $250.98, which may present a buying opportunity for investors looking for growth in the biopharmaceutical space.

Cons

  • The company reported a significant earnings miss with an EPS of ($0.87), falling short of the consensus estimate of ($0.51), which raises concerns about its profitability and operational efficiency.
  • Quarterly revenue decreased by 33.3% year-over-year, indicating potential challenges in maintaining sales momentum and market share, which could impact future growth prospects.
  • Analysts forecast a negative EPS of -2.21 for the current year, suggesting ongoing financial difficulties that may deter potential investors.
DexCom logo

#46 - DexCom

NASDAQ:DXCM - See Stock Forecast
Stock Price:
$80.04 (+$4.22)
Market Cap:
$31.26 billion
P/E Ratio:
47.9
Consensus Rating:
Moderate Buy (1 Strong Buy Ratings, 11 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$98.00 (22.4% Upside)
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of DexCom Stock

Pros

  • DexCom, Inc. has a strong market capitalization of approximately $30.83 billion, indicating a robust financial position and potential for growth.
  • The stock is currently trading at $78.93, which may present a buying opportunity for investors looking for value in the medical device sector.
  • Recent analyst upgrades, including a target price increase from Wells Fargo & Company to $90.00, suggest positive market sentiment and potential for stock appreciation.

Cons

  • The stock has experienced volatility, with a recent trading down of 1.9%, indicating potential instability in the short term.
  • Insider selling, including a recent transaction where an executive sold 4,259 shares, may raise concerns about the company's future performance and insider confidence.
  • Despite positive analyst ratings, the stock has a high price-to-earnings (P/E) ratio of 47.26, which could suggest that it is overvalued compared to its earnings.
Centene logo

#47 - Centene

NYSE:CNC - See Stock Forecast
Stock Price:
$59.58 (-$0.13)
Market Cap:
$30.08 billion
P/E Ratio:
10.3
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 9 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings)
Consensus Price Target:
$80.92 (35.8% Upside)
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Centene Stock

Pros

  • Recent insider buying activity, including a significant purchase by the CFO of 17,200 shares at an average price of $58.14, indicates confidence in the company's future performance.
  • The stock is currently trading at approximately $56.76, which is near its 12-month low of $56.44, potentially offering a buying opportunity for investors looking for value.
  • Centene Co. has a strong market presence in the healthcare sector, providing essential services to under-insured and uninsured families, which can lead to stable revenue streams.

Cons

  • Recent price target reductions by analysts, including a drop from $83.00 to $66.00, may indicate a bearish outlook on the stock's future performance.
  • The stock has experienced significant volatility, with a 12-month high of $81.42, suggesting potential risks for investors if the price continues to fluctuate.
  • Despite recent insider purchases, the overall market sentiment appears cautious, with several analysts issuing hold ratings, which may limit upside potential.
Humana logo

#48 - Humana

NYSE:HUM - See Stock Forecast
Stock Price:
$247.10 (+$11.32)
Market Cap:
$29.75 billion
P/E Ratio:
21.9
Dividend Yield:
1.48%
Consensus Rating:
Hold (0 Strong Buy Ratings, 6 Buy Ratings, 19 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$300.50 (21.6% Upside)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Humana Stock

Pros

  • Humana Inc. reported strong earnings of $4.16 per share, significantly exceeding analysts' expectations of $3.48, indicating robust financial performance and effective management.
  • The company has a solid market capitalization of approximately $33.80 billion, which reflects its stability and potential for growth in the insurance sector.
  • Recent institutional investments, such as Two Sigma Advisers LP acquiring an additional 24,500 shares, suggest confidence in Humana Inc.'s future prospects, as institutional investors often conduct thorough research before making significant investments.

Cons

  • The stock has experienced significant volatility, with a 12-month low of $213.31, which may raise concerns about its stability and the potential for further declines.
  • Humana Inc. has a relatively high price-to-earnings (P/E) ratio of 25.07, which could indicate that the stock is overvalued compared to its earnings, making it a riskier investment.
  • The company has a net margin of only 1.18%, suggesting that it retains a small portion of revenue as profit, which may limit its ability to reinvest in growth or return capital to shareholders.
Cardinal Health logo

#49 - Cardinal Health

NYSE:CAH - See Stock Forecast
Stock Price:
$118.28 (+$1.28)
Market Cap:
$28.62 billion
P/E Ratio:
23.0
Dividend Yield:
1.75%
Consensus Rating:
Moderate Buy (0 Strong Buy Ratings, 8 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$127.50 (7.8% Upside)
Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Cardinal Health Stock

Pros

  • Cardinal Health, Inc. has recently received positive upgrades from multiple analysts, with price targets raised significantly, indicating strong market confidence. For instance, Argus increased their target from $115.00 to $125.00, suggesting potential for price appreciation.
  • The current stock price is $117.16, which is below the average price target of $124.58, indicating that there may be room for growth in the stock value.
  • Despite a slight decline in quarterly revenue, the company reported earnings per share (EPS) of $1.88, surpassing analysts' expectations of $1.62, which reflects strong operational performance.

Cons

  • Cardinal Health, Inc. experienced a year-over-year revenue decline of 4.3%, which may raise concerns about the company's growth prospects and market competitiveness.
  • The company has a negative return on equity of 56.56%, indicating that it is currently not generating profit from its equity investments, which could deter potential investors.
  • One analyst has rated the stock with a sell rating, which may signal caution among some investors regarding the stock's future performance.
Cerner logo

#50 - Cerner

NASDAQ:CERN - See Stock Forecast
Stock Price:
$94.92
Market Cap:
$27.92 billion
P/E Ratio:
47.7
Dividend Yield:
1.14%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Cerner Corporation, together with its subsidiaries, provides health care information technology solutions and tech-enabled services in the United States and internationally. It offers Cerner Millennium architecture, a person-centric computing framework, which includes clinical, financial, and management information systems that allow providers to access an individual's electronic health record (EHR) at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. The company also provides HealtheIntent platform, a cloud-based platform to aggregate, transform, and reconcile data across the continuum of care; and CareAware, an EHR agnostic platform that facilitates connectivity of health care devices to EHRs. In addition, it offers a portfolio of clinical and financial healthcare information technology solutions, as well as departmental and care coordination solutions. Further, the company provides tech-enabled services, such as implementation and training, remote hosting, application management, revenue cycle, support and maintenance, health care data analysis, real-world evidence, clinical process optimization, transaction processing, employer health centers, and data-driven services; and complementary hardware and devices for third parties. It serves integrated delivery networks, physician groups and networks, managed care organizations, hospitals, medical centers, free-standing reference laboratories, home health agencies, blood banks, imaging centers, pharmacies, pharmaceutical manufacturers, employers, governments, and public health organizations. The company was founded in 1979 and is headquartered in North Kansas City, Missouri.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.

Pros and Cons of Cerner Stock

Pros

  • Cerner Co. has a strong position in the health care technology sector, providing essential solutions like the Cerner Millennium architecture, which enhances patient care by giving healthcare providers access to comprehensive electronic health records (EHR) at the point of care.
  • The company’s HealtheIntent platform is a cutting-edge cloud-based solution that aggregates and reconciles data across the continuum of care, making it a valuable asset for healthcare organizations looking to improve data management and patient outcomes.
  • As of December 2024, Cerner Co.'s stock price is competitive, reflecting investor confidence in its growth potential and market position, which can lead to capital appreciation for shareholders.

Cons

  • Despite its strong offerings, Cerner Co. faces intense competition in the health care technology space, which could pressure margins and market share as new entrants and established players innovate rapidly.
  • The company’s reliance on government contracts and regulations can pose risks, as changes in healthcare policies or funding could impact revenue stability and growth prospects.
  • Recent economic uncertainties and fluctuations in the stock market may affect investor sentiment towards tech stocks, including Cerner Co., leading to potential volatility in its stock price.

(Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

More Stock Ideas from MarketBeat